Journal of Clinical Epidemiology
Volume 52, Issue 2 , Pages 95-103 , February 1999

Relation of Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate with Cardiovascular Disease Risk Factors in Women: Longitudinal Results from the Massachusetts Women’s Health Study

  • Catherine B Johannes

      Affiliations

    • New England Research Institutes, Watertown, MA USA
    • Corresponding Author InformationAddress for correspondence: Dr. Catherine B. Johannes, New England Research Institutes, 9 Galen Street, Watertown, MA 02472
    • ,
  • Rebecca K Stellato

      Affiliations

    • New England Research Institutes, Watertown, MA USA
    • ,
  • Henry A Feldman

      Affiliations

    • New England Research Institutes, Watertown, MA USA
    • ,
  • Christopher Longcope

      Affiliations

    • University of Massachusetts Medical Center, Worcester, MA USA
    • ,
  • John B McKinlay

      Affiliations

    • New England Research Institutes, Watertown, MA USA

,Accepted 1 September 1998.

References 

  1. Kask E. 17-ketosteroids and arteriosclerosis. Angiology. 1959;10:358–368
  2. Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate (Their relation to cardiovascular disease). Epidemiol Rev. 1991;13:267–293
  3. Orentreich N, Brind JL, Rizer RL. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551–555
  4. Orentriech N, Brind JL, Vogelmen JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab. 1992;75:1002–1004
  5. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone (A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury). J Clin Invest. 1988;82:712–720
  6. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 1990;16:862–870
  7. Mitchell LE, Sprecher DL, Boreki JB, Rice T, Laskarezewski PM, Rao DC. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation. 1994;89:89–93
  8. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman M, et al.  Decreased plasma dehydroepiandrosterone concentrations in young men after myocardial infarction. Atherosclerosis. 1989;79:197–203
  9. Slowinska-Srzednicka J, Makczewska B, Srzednicki M, et al.  Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med. 1995;237:465–472
  10. Barrett-Connor E, Khaw K-T, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519–1524
  11. LaCroix AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction and extent of atherosclerosis in men. Circulation. 1992;86:1529–1535
  12. Schaefer C, Friedman G, Ettinger B, Quesenberry C, Liu J, Haan M, et al. Dehydroepiandrosterone sulfate (DHEAS), angina, and fatal ischemic heart disease. (Abstract). Am J Epidemiol. 1996;143:S69
  13. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians (A prospective study). Am J Epidemiol. 1994;140:870–875
  14. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease (A quantitative assessment of the epidemiologic evidence). Preven Med. 1991;20:47–63
  15. Barrett-Connor E, Khaw K-T. The epidemiology of DHEAS with particular reference to cardiovascular disease (The Rancho Bernardo Study). In:  Kalimi M,  Regelson W editor. The Biologic Role of Dehydroepiandrosterone (DHEA). Berlin, Germany: Walter De Gruyter & Co; 1990;
  16. Barrett-Connor E, Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med. 1987;317:711
  17. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation. 1995;91:1757–1760
  18. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol. 1988;158:1553–1560
  19. Consensus Development Panel on Triglyceride NIH, High-Density Lipoprotein , Coronary Heart Disease . Tryclyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505–510
  20. Nafziger AN, Jenkins PL, Bowlin SJ, Pearson TA. Dehydroepiandrosterone, lipids, and apoproteins (Associations in a free-living population. (Abstract)). Circulation. 1990;82(Suppl III):III–469
  21. Haffner SM, Newcomb PA, Marcus PM, Klein BEK, Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-SO4) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol. 1995;142:925–934
  22. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. In (Bellino FL, Daynes RA, Hornsby PJ, Lavrin DH, Nestler JE, Eds. Dehydroepiandrosterone (DHEA) and Aging). Annals NY Acad Sci. 1995;774:259–270
  23. Newcomb PA, Klein R, Klein BEK, Haffner S, Mares-Perlman J, Cruickshanks KJ, et al. Association of dietary and lifestyle factors with sex hormones in postmenopausal women. Epidemiology. 1995;6:318–321
  24. McKinlay JB, McKinlay SM, Brambilla DJ. Health status and utilization behavior associated with menopause. Am J Epidemiol. 1987;125:110–121
  25. Longcope C, Herbert PN, McKinlay SM, Goldfield SR. The relationship of total and free estrogens and sex hormone-binding globulin with lipoproteins in women. J Clin Endocrinol Metab. 1990;71:67–72
  26. Longcope C, Watson D, Williams KIH. The effects of synthetic estrogens on the metabolic clearance and production rates of estrone and estradiol. Steroids. 1974;24:15–30
  27. Longcope C, Hui SL, Johnston CC. Free estradiol, free testosterone and sex hormone binding globulin in peri-menopausal women. J Clin Endocrinol Metab. 1987;64:513–518
  28. Franz C, Watson D, Longcope C. Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids. 1979;34:563–573
  29. Longcope C, Bourget C, Flood C. The production and aromatization of dehydroepiandrosterone in postmenopausal women. Maturitas. 1987;4:325–332
  30. Sady SP, Thompson PD, Cullinane EM, Kantor MA, Domagala E, Herbert PN. Prolonged exercise augments plasma triglyceride clearance. JAMA. 1986;256:2552–2555
  31. Herbert PN, Hyams JS, Bernier DN, et al.  Apolipoprotein B-100 deficiency (Intestinal steatosis despite apolipoprotein B-48 synthesis). J Clin Invest. 1985;76:403–412
  32. Khavari KA, Farber PD. A profile instrument for the quantification and assessment of alcohol consumption. J Stud Alcohol. 1978;39:1525–1539
  33. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;72:13–22
  34. Kannell WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med. 1976;85:447–452
  35. Razay G, Heaton KW, Bolton CH. Coronary heart disease risk factors in relation to the menopause. Q J Med. 1992;85:307–308889–896
  36. Longcope C, Franz D, Morello C, Baker R, Johnston CC. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas. 1986;8:189–196
  37. Zumoff B, Rosenfeld RS, Strain GW, Levin J, Fulushima DK. Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHS) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocrinol Metab. 1980;51:330–333
  38. Johannes CB, Feldman HA, Stellato RK, McKinlay SM. The effect of the menopausal transition and aging on DHEAS levels in women. (Abstract). Am J Epidemiol. 1996;143:S64
  39. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem. 1988;34:2456–2459
  40. Rifai N, Merrill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem. 1990;27:489–493
  41. Wilson PWF. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66:7A–10A
  42. DHEA Info Page DHEA Ultra, World Wide Web, http://thayne.simlenet.com/dhea/ultra1.html, 11/10/97.
  43. DHEA Connection, World Wide Web, http://www.tusconlink.com/dheaconn/dheares.htm, 11/10/97.
  44. Labrie F, Belanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation (Intracrinology. In: Bellino FL, Daynes RA, Hornsby PJ, Lavrin DH, Nestler JE, Eds. Dehydroepiandrosterone (DHEA) and Aging). Ann NY Acad Sci. 1995;774:16–28
  45. Schwartz AG, Fairman DK, Paschko LL. The biological significant of dehydroepiandrosterone. In:  Kalimi MN,  Regelson W editor. The Biologic Role of Dehydroepiandrosterone (DHEA). Berlin, Germany: Walter De Gruyter & Co; 1990;
  46. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 1990;71:696–704
  47. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360–1367
  48. Khaw K-T. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J Endocrinol. 1996;150:S149–S153

PII: S0895-4356(98)00144-9

Journal of Clinical Epidemiology
Volume 52, Issue 2 , Pages 95-103 , February 1999

Article Tools